Annals of Oncology Advance Access originally published online on December 19, 2005
Annals of Oncology 2006 17(5):735-749; doi:10.1093/annonc/mdj100
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
review |
Novel formulations of taxanes: a review. Old wine in a new bottle?
1 St Louis College of Pharmacy, Ortho Biotech Clinical Affairs, LLC, St Louis, MO; 2 Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
* Correspondence to: Dr R. Govindan, Division of Medical Oncology, Washington University School of Medicine, 4960 Children's Place, Box 8056, St Louis, MO 63110, USA. Tel: +1-314-362-4819; Fax: +1-314-362-7086; E-mail: rgovinda{at}im.wustl.edu
Over the past two decades, the taxanes have played a significant role in the treatment of various malignancies. However, the poor solubility of these compounds necessitates the inclusion of surfactant vehicles in their commercial formulations. Cremophor EL and polysorbate 80 have long comprised the standard solvent system for paclitaxel and docetaxel, respectively. A number of pharmacologic and biologic effects related to both of these drug formulations have been described, including clinically relevant acute hypersensitivity reactions and peripheral neuropathy. In addition, these solvents affect the disposition of intravenously administered solubilized drugs and leach plasticizers from polyvinylchloride infusion sets. A number of strategies to develop formulations of surfactant-free taxanes have been developed. They include albumin nanoparticles, polyglutamates, taxane analogs and prodrugs, emulsions, and lipsomes. An overview of these novel formulations of taxanes, their mechanisms of action, pharmacokinetics, dose and administration, adverse effects, and clinical efficacy will be discussed.
Key words: novel formulations, taxanes, vehicles
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Goodin Novel cytotoxic agents: Epothilones Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason 130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Goldstein, O. Gofrit, A. Nyska, and S. Benita Anti-HER2 Cationic Immunoemulsion as a Potential Targeted Drug Delivery System for the Treatment of Prostate Cancer Cancer Res., January 1, 2007; 67(1): 269 - 275. [Abstract] [Full Text] [PDF]
|
|